INTRODUCTION {#S5}
============

In Pompe disease (OMIM 232300; acid maltase deficiency, glycogen storage disease type II), a deficiency of lysosomal acid alpha-glucosidase (GAA) leads to the accumulation of glycogen in skeletal, cardiac and smooth muscle, resulting in progressive, debilitating muscle weakness. If left untreated, infants with the classic infantile form of Pompe disease typically succumb to the disease by cardiopulmonary failure within the first two years of life. However, intravenous enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA), or alglucosidase alfa (Lumizyme^®^), has improved clinical outcomes and prolonged survival in patients with infantile Pompe disease (IPD).

Despite improved clinical outcomes including prolonged overall and ventilator-free survival in IPD patients^[@R1]--[@R4]^, the efficacy of ERT is diminished for some patients who mount an immune response against rhGAA. Previous studies have demonstrated that cross reactive immunologic material (CRIM) status is highly correlated with clinical response to treatment^[@R5],[@R6]^. CRIM-positive (CP) patients generally respond well to ERT due to the presence of residual GAA expression. On the other hand, patients with no residual protein expression are categorized as CRIM-negative (CN). In general, when compared to CP patients who tolerize to ERT over time, CN patients mount an immune response against rhGAA resulting in significant clinical decline and ultimately ventilator dependence or death by 27.1 months despite continuation of ERT^[@R5]^.

Physicians caring for patients treated with a therapeutic protein such as rhGAA in IPD are thus charged with the challenge of also managing significant immune responses. Our group has demonstrated the success of immune tolerance induction (ITI) protocols along with ERT in both the naïve setting, to prevent the development of high antibody titers^[@R7]--[@R9]^, and also in the entrenched setting, to suppress an immune response once high antibody titers have already developed^[@R6],[@R10]^. However, ITI has proved to be most successful in the naïve setting, which requires a short 5-week regimen of immune modulation initiated at the start of ERT compared to a significantly longer, multipronged approach for treating patients with an entrenched immune response to the rhGAA^[@R6],[@R10]^.

Current literature reflects how clinical outcomes of CN patients treated with ERT+ITI surpass those on ERT monotherapy^[@R9]^. However, three cases have been reported in which CN patients have done relatively well, clinically, in the absence of high sustained antibody titers (HSAT) without the use of ITI^[@R11],[@R12]^. Yet, it is important to note that one of these patients received omalizumab, an IgG monoclonal antibody which binds IgE, for severe allergic reaction to alglucosidase alfa infusion^[@R11]^. The role of this drug in immunomodulation is yet to be reported.

As the use of ITI protocols is becoming more prevalent, it is important to understand the factors influencing immune responses in the CN IPD population, as such knowledge is essential for guiding further implementation of ITI protocols. However, a fundamental understanding of the long-term clinical outcomes of CN IPD patients treated with ERT alone (ERT monotherapy) is missing. In this study we aimed to retrospectively assess the immune responses in our cohort of CN IPD patients receiving rhGAA, which we believe is the largest in the world. We did this in order to determine what proportion of CN patients develop significant immune responses, which negatively affect clinical outcomes, and to consider the influence of potentially modifying factors in the development of an immune response, such as *GAA* genotype or age at which ERT is initiated. This cohort represents an invaluable set of data with a unique opportunity to examine responses to ERT alone, especially as the treatment paradigm for CN IPD patients continues to shift toward the implementation of ITI in the naïve setting.

PATIENTS AND METHODS {#S6}
====================

This was a retrospective chart review of our large cohort of 183 total IPD patients from our previously published cohort^[@R5]^ and enrolled in Duke Institutional Review Board (IRB)-approved protocol 00001562 \[LDN6709 Site 206; [Clinicaltrials.gov](http://Clinicaltrials.gov) Identifier: NCT01665326\] for CRIM determination and longitudinal follow-up. Of those, we identified 58 patients who were determined to be CN, 20 of whom were treated with alglucosidase alfa ERT monotherapy for at least 6 months at cumulative doses of 20 to 40 milligrams per kilogram every two weeks. We included patients who had been on ITI regimens that were unsuccessful in preventing the development of HSAT. We also included one patient (Patient 10; HSAT group) who was successfully treated with ITI in the entrenched setting; data were used until ITI was initiated at week 87. Patients were excluded from data analysis if there was administration of ITI in the naïve setting.

Laboratory Methods {#S7}
------------------

CN status was first determined based on reactivity of a pool of monoclonal and/or polyclonal anti-rhGAA antibodies capable of recognizing both native and recombinant GAA protein bands, using western blot analysis on skin fibroblast cell extracts. If none of the GAA protein forms (unprocessed precursor band at 110 kDa or processed forms bands at 95, 76 and 70 kDa) were detected, the patient is categorized as CN^[@R5]^. In one case, CN status was determined using western blot analysis of amniocytes following the prior diagnosis of the proband sibling^[@R12]^. For all patients, final CN status was assigned once the results of western blot analysis were correlated with *GAA* mutation genotype^[@R13]^.

Anti-rhGAA IgG Antibodies {#S8}
-------------------------

Anti-rhGAA IgG antibodies were ascertained using enzyme-linked immunosorbent assays and confirmed using radioimmunoprecipitation as described previously^[@R2]^ and assessed by Genzyme Corporation (Framingham, MA) at baseline and at regular intervals throughout treatment. CN IPD patients were further divided into three groups based on anti-rhGAA antibody titer levels and the need for further clinical intervention^[@R6],[@R14]^: HSAT group: Anti-rhGAA IgG antibodies measured ≥51,200 on two or more occasions after six months on ERT;Low titer (LT) group: IgG antibodies remained \<6,400 throughout the course of ERT; andSustained intermediate titer (SIT) group: IgG antibodies ranged 6,400--25,600.

Clinical Parameters {#S9}
-------------------

Baseline and follow-up data were obtained to assess treatment outcomes in these three groups including age at diagnosis, age at initiation of ERT, invasive ventilator-free survival, overall survival and left ventricular mass index (LVMI).

Statistical Analysis {#S10}
--------------------

Survival data were analyzed using the Kaplan--Meier method with two-tailed P values generated using the log-rank test^[@R15]^. Analyses were performed with STATA version 13.1 (StataCorp LP, College Station, Texas). Due to small sample size, descriptive data are presented as medians.

RESULTS {#S11}
=======

Of our total IPD cohort, established between 1999 through February 1, 2014 (n=183), 58 were identified as CN, which to our knowledge represents the largest CN IPD cohort in current literature. From this group, 23 CN IPD were excluded from analysis because ITI treatment was administered in the naïve setting; for 15 other CN IPD patients, death occurred before six months on ERT or there was insufficient follow-up data; thus, the resulting data analysis included 20 CN IPD patients ([Figure 1](#F1){ref-type="fig"}).

Anti-rhGAA antibody titers {#S12}
--------------------------

The majority (85%) of CN patients (17/20) developed clinically significant IgG antibody titers to rhGAA. Thirteen mounted HSAT with median peak titers of 204,800 by 24 weeks on ERT ([Table 1](#T1){ref-type="table"}). Four patients had SIT with peak titers of 25,600 and 51,200. Three patients had LT peaking at 200 (n=2) and 800 (n=1).

Spectrum of *GAA* Mutations {#S13}
---------------------------

We identified *GAA* mutations in our cohort ([Table 2](#T2){ref-type="table"}) and assessed the types of mutations seen in each titer group ([Figure S1](#SD1){ref-type="supplementary-material"}). Ten of 13 patients in the HSAT group carried at least one nonsense mutation. Total nonsense mutations frequency observed in HSAT group was 18 /26 total alleles (69%), frameshift mutation allele frequency was 7/26 alleles (27%) and splice site mutation allele frequency was 1/26 alleles (4%). Three of eight alleles (38%) in the SIT group were frameshift mutations, two (25%) were missense initiator codon mutations, two (25%) were nonsense mutations and one (13%) was a splice site mutation. Three out of six alleles (50%) observed in the LT group were splice site mutations and three (50%) were frameshift mutations. All patients were unrelated with the exception of one sib-pair (Patient 14 of the SIT group and Patient 18 of the LT group) who were compound heterozygotes for the c.546+2\_+5delTGGG splice site mutation and c.1650dupG frameshift mutation, as first reported by Al Khallaf et al^[@R12]^. Unlike the SIT and HSAT groups, no patient in the LT group carried a nonsense mutation.

Clinical Parameters {#S14}
-------------------

[Table 3](#T3){ref-type="table"} provides demographic and clinical parameters for this international cohort of CN IPD on ERT monotherapy. Four patients started ERT before one month of age with variable clinical outcomes: while two have not developed an immune response against rhGAA (Patient 18 and 20), two others responded poorly with death at 18 and 45 months of age (Patient 9 and 16). Thus, it appears that early initiation of ERT does not necessarily prevent development of an antibody response to ERT.

Invasive Ventilator-Free and Overall Survival {#S15}
---------------------------------------------

No patients required invasive ventilator support at baseline; however, 55% required invasive ventilation by a median age of 13.8 months (range: 8.2--33.6 months, n=11) ([Figure 2A](#F2){ref-type="fig"}). Four patients (20%) died (median age of death: 23.1 months; range: 18.0--45.0 months) prior to requiring invasive ventilation and the remaining five patients (25%) are alive and invasive ventilator free. Among the patients who died during the study period, the median age of death was 32.5 months (range: 14.7--50.2 months, n=14) ([Figure 2B](#F2){ref-type="fig"}). For the HSAT group, the median age of death was also 32.5 months (range: 14.7 to 50.2 months, n=12) and 13.8 months for ventilator-dependence (range: 8.2 to 33.6 months, n=11), similar to previously published data^[@R5]^. Only one patient from the HSAT group is currently alive; this patient received ITI treatment in the entrenched setting^[@R10]^.

Left Ventricular Mass Index {#S16}
---------------------------

In this study, all groups had an elevated LVMI at baseline compared to the normal upper limit of 64 g/m^2^ for infants without Pompe disease^[@R18]^. The median LVMI for the HSAT group was 180.5 g/m^2^ at baseline (range: 89.0 to 253.0 g/m^2^; n=10). A net decrease was observed at 26 weeks on ERT (median=95.0 g/m^2^; range: 56.7 to 269.0 g/m^2^; n=11) followed by a net increase at 52 weeks on ERT (median=124.8 g/m^2^; range: 63.3 to 178.0 g/m^2^ n=8). For the HSAT group, the median LVMI continued to increase after week 52 of ERT (n=3; data not shown). Patient 18 of the LT group had an LVMI of 128.3 g/m^2^ and 50.8 g/m^2^ at baseline and week 111, respectively, not demonstrating a worsening in LVMI after week 52 as was seen in the HSAT group. Patient 20 in the LT group had an LVMI of 68 g/m^2^, 65 g/m^2^ and 58 g/m^2^ at baseline, week 30 and week 60, respectively. One patient with SIT (Patient 15) had LVMI measurements behaving similar to those seen in the HSAT group (203 g/m^2^ at baseline, 138 g/m^2^ at week 26 and 200 g/m^2^ at week 52), while another SIT patient's baseline LVMI of 141.5 g/m^2^ normalized after 9 months of treatment (Patient 16)---consistent with those in the LT group.

DISCUSSION {#S17}
==========

Similar to what has been previously noted, approximately 32% of our IPD cohort were determined to be CN---a clinical factor predicting reduced survival and poor clinical outcomes compared to CP patients^[@R5]^, specifically related to the development of HSAT in response to rhGAA^[@R6]^. The use of ITI protocols has changed the natural history of CN IPD with a significant difference in survival compared to CN IPD treated with ERT monotherapy^[@R9]^. Interestingly, only three CN cases have been reported in the literature to date that have not developed a significant immune response against rhGAA without the use of ITI^[@R11],[@R12]^, which suggests the presence of other modifying or protective factors influencing treatment outcomes in these cases.

Given the advent of newborn screening for Pompe disease, we sought to determine if early initiation of ERT prevents the development of an immune response. As previously noted, despite early initiation of treatment, the majority of CN IPD patients developed sustained antibodies against rhGAA, many of whom mounted HSAT associated with subsequent clinical decline and ultimately death, including some patients who started ERT before one month of age^[@R19]^. Therefore, in contrast to previous claims^[@R12]^, early initiation of ERT does not protect against the development of an immune response against rhGAA^[@R20]^.

While two CN patients with early initiation of ERT did not develop a clinically significant immune response, both carried splice site mutations. As such, the patients may have been exposed to GAA epitopes similar to rhGAA if these mutations allowed for residual GAA production, yet at a level below detection by traditional western blot analysis. A closer look at the types of *GAA* mutations in our cohort showed that most of the patients with HSAT had at least one nonsense *GAA* mutation. In contrast, CN patients in the LT group exclusively carried splicing or frameshift *GAA* mutations, none of which were nonsense mutations.

Leaky splice site mutations or premature stop codons which occur toward the end of the *GAA* coding region may possibly result in some residual enzyme activity, which in turn helps prevent the development of an immune response to ERT. The current understanding of CRIM status is based on results from western blot; however, without correlation of *GAA* mutations, western blot may not provide the entire picture. Utilization of additional technologies, such as an "omics" approach, may be warranted to identify potential modifying or protective factors and reach a more complete understanding of immune responses in IPD. Additionally, the definitive role of various *GAA* mutations in the protein expression as well as the possibility of variable tissue expression needs further exploration.

In conclusion, very few CN patients have been reported with no immune response; however, these patients have unique genotypes frequently with splicing mutations, whose various degrees of immunogenicity needs to be further explored. This study confirms that CN status yields an overall poor clinical response, as the majority of CN IPD patients treated with ERT monotherapy develop an immune response and experience subsequent clinical decline or death. On the contrary, development of anti-rhGAA antibody titers appears to be dictated by the presence of *GAA* mutations known to severely affect protein expression; thus, results of western blot analysis should be correlated with *GAA* genotype for the confirmation of CRIM status in IPD. While early diagnosis and treatment is significant in improving overall clinical outcomes in IPD, early diagnosis and initiation of treatment by itself does not prevent the development of antibodies against rhGAA. ITI in the naïve setting has proven to be successful in preventing the development of antibody titers in CN IPD, which validates the use of ITI therapies in the ERT-naïve setting. Because immunological responses accompanied with clinical decline poses a significant risk for the CN IPD population, implementation of ITI in the naïve setting should be considered standard of care in treating these patients at risk to develop HSAT. Further investigation surrounding immune responses and management of IPD, irrespective of CRIM status, is required and warrants attention, particularly in the setting of newborn screening for Pompe disease.

Supplementary Material {#SM}
======================

###### Figure S1. *GAA* Mutations Observed in HSAT, SIT and LT Groups

HSAT, high sustained antibody titers; LT, low titers; SIT, sustained intermediate titers
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![Cohort of infantile Pompe disease patients\
^†^ n=1 rescued with an ITI protocol in the entrenched setting after six months on ERT; therefore, data for this patient was included up until the initiation of ITI^[@R10]^; n=2 included as ITI regimen was unsuccessful with persistence of antibody titers^[@R16],[@R17]^\
IPD, infantile Pompe disease; CN, CRIM, cross reactive immunologic material (CRIM); CN, CRIM-negative; CP, CRIM-positive; ERT, enzyme replacement therapy; ITI, immune tolerance induction](nihms654429f1){#F1}

###### Kaplan-Meier Curves\* for (A) overall survival and (B) ventilator-free survival for HSAT, SIT, and LT groups

\(A\) Overall survival for HSAT, SIT, and LT groups

\(B\) Invasive ventilator-free survival for HSAT, SIT, and LT groups

\* Patient 10 was successfully rescued using ITI at 86 weeks and was excluded in these calculations

HSAT, high sustained antibody titers; LT, low titers; SIT, sustained intermediate titers
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###### 

Antibody response in HSAT, SIT and LT groups at peak titer and last titer measurements

  ----------------------------------------------------------------------------------------------------------------------------
  Group   Patient     Peak titers           Weeks on ERT at\                          Last titers           Weeks on ERT at\
                                            peak titers                                                     last titers
  ------- ----------- --------------------- ----------------------------------------- --------------------- ------------------
  HSAT    1           204 800               78                                        102 400               152

  2       204 800     60                    102 400                                   181                   

  3       102 400     24                    51 200                                    36                    

  4       204 800     64                    204 800                                   64                    

  5       409 600     64                    409 600                                   82                    

  6       1 638 400   52                    1 638 400                                 64                    

  7       204 800     38                    102 400                                   52                    

  8       51 200      24                    25 600                                    38                    

  9       409 600     64                    409 600                                   64                    

  10      819 200     86                    819 200[\*](#TFN1){ref-type="table-fn"}   86                    

  11      51 200      28                    51 200                                    63                    

  12      819 200     130                   409 600                                   138                   

  13      819 200     29                    819 200                                   29                    

          Median      204 800               60                                        204 800               64

          Range       51 200 -- 1 638 400   24 -- 130                                 25 600 -- 1 638 400   29 -- 181

  SIT     14          51 200                15                                        6 400                 202

  15      25 600      16                    6 400                                     90                    

  16      25 600      117                   6 400                                     194                   

  17      25 600      24                    12 800                                    132                   

          Median      25 600                20                                        6 400                 145

          Range       25 600 -- 51 200      15 -- 117                                 6 400 -- 25 600       90 -- 202

  LT      18          800                   26                                        100                   112

  19      200         100                   100                                       110                   

  20      200         48                    0                                         84                    

          Median      200                   48                                        100                   110

          Range       200 -- 800            26 -- 100                                 0 -- 100              84 -- 112
  ----------------------------------------------------------------------------------------------------------------------------

Indicates the last titer value before the initiation of ITI

HSAT, high sustained antibody titers; LT, low titers; SIT, sustained intermediate titers; ITI, immune tolerance induction

###### 

*GAA* mutations identified in CRIM-negative infantile Pompe disease cohort

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group   Patient                     Allele 1 cDNA change        Allele 2 cDNA change   Allele 1 amino\     Allele 2 amino acid\   Allele 1\         Allele 2\     Allele 1\                               Allele 2\
                                                                                         acid change         change                 mutation\         mutation\     mutation\                               mutation\
                                                                                                                                    type              type          effect[†](#TFN3){ref-type="table-fn"}   effect[†](#TFN3){ref-type="table-fn"}
  ------- --------------------------- --------------------------- ---------------------- ------------------- ---------------------- ----------------- ------------- --------------------------------------- ---------------------------------------
  HSAT    1                           c.722_723delTT              c.1687C\>T             p.Phe241CysfsX88    p.Gln563X              Frameshift        Nonsense      very severe                             very severe

  2       c.1687C\>T                  c.1687C\>T                  p.Gln563X              p.Gln563X           Nonsense               Nonsense          very severe   very severe                             

  3       c.148_859-11del             c.685_686insCGGC            p.Glu50HisfsX37        p.Arg229ProfsX102   Frameshift             Frameshift        very severe   very severe                             

  4       c.2560C\>T                  c.2560C\>T                  p.Arg854X              p.Arg854X           Nonsense               Nonsense          very severe   very severe                             

  5       c.1075G\>T                  c.1075G\>T                  p.Gly359X              p.Gly359X           Nonsense               Nonsense          unknown       unknown                                 

  6       c.2560C\>T                  c.2560C\>T                  p.Arg854X              p.Arg854X           Nonsense               Nonsense          very severe   very severe                             

  7       c.2560C\>T                  c.2560C\>T                  p.Arg854X              p.Arg854X           Nonsense               Nonsense          very severe   very severe                             

  8       c.722_723delTT              c.1754 +1G\>A               p.Phe241CysfsX88       Splice Site         Frameshift             Splice Site       very severe   unknown                                 

  9       c.1496G\>A                  c.1496G\>A                  p.Trp499X              p.Trp499X           Nonsense               Nonsense          very severe   very severe                             

  10      c.1654delC                  c.2560C\>T                  p.Leu552SerfsX26       p.Arg854X           Frameshift             Nonsense          unknown       very severe                             

  11      c.2560C\>T                  c.2560C\>T                  p.Arg854X              p.Arg854X           Nonsense               Nonsense          very severe   very severe                             

  12      c.1826dupA                  c.2238G\>A                  p.Tyr609X              p.Trp746X           Nonsense               Nonsense          very severe   very severe                             

  13      c.2222\_\*549+214delins13   c.2222\_\*549+214delins13   p.Asp741AlafsX28       p.Asp741AlafsX28    Frameshift             Frameshift        unknown       unknown                                 

  SIT     14                          c.546+2_546+5delTGGG        c.1650dupG             Splice Site         p.Thr551AspfsX85       Splice Site       Frameshift    very severe                             unknown

  15      c.1209delC                  c.1209delC                  p.Asn403LysfsX37       p.Asn403LysfsX37    Frameshift             Frameshift        unknown       unknown                                 

  16      c.2560C\>T                  c.2560C\>T                  p.Arg854X              p.Arg854X           Nonsense               Nonsense          very severe   very severe                             

  17      c.1A\>G                     c.1A\>G                     p.Met1?                p.Met1?             Initiator codon        Initiator codon   unknown       unknown                                 

  LT      18                          c.546+2_546+5delTGGG        c.1650dupG             Splice Site         p.Thr551AspfsX85       Splice Site       Frameshift    very severe                             unknown

  19      c.2495_2496delCA            c.2495_2496delCA            p.Thr832AsnfsX51       p.Thr832AsnfsX51    Frameshift             Frameshift        very severe   very severe                             

  20      c.1637-2A\>G                c.1637-2A\>G                Splice Site            Splice Site         Splice Site            Splice Site       very severe   very severe                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Source: Erasmus MC Rotterdam; <http://www.pompecenter.nl>

HSAT, high sustained antibody titers; LT, low titers; SIT, sustained intermediate titers

###### 

Demographic and Clinical Parameters of CN IPD Cohort

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Group   Patient   Gender   Race   Age at ERT[†](#TFN5){ref-type="table-fn"}\   Baseline\      Baseline\       Age at\              Deceased\
                                    (months)                                     invasive\      LVMI (g/m^2^)   death/current age\   (Y/N)
                                                                                 ventilation\                   (months)             
                                                                                 (Y/N)                                               
  ------- --------- -------- ------ -------------------------------------------- -------------- --------------- -------------------- -----------
  HSAT    1         M        W      3.5                                          N              253.0           50.2                 Y

  2       M         B        2.8    N                                            160.0          44.8            Y                    

  3       M         A        3.9    N                                            157.2          14.7            Y                    

  4       F         A        2.7    N                                            246.7          23.3            Y                    

  5       F         W        6.1    N                                            N/A            25.5            Y                    

  6       F         B        1.8    N                                            153.0          32.0            Y                    

  7       M         B        5.6    N                                            202.1          45.0            Y                    

  8       F         W        1.8    N                                            233.4          44.6            Y                    

  9       M         W        −0.3   N                                            89.0           18.0            Y                    

  10      M         W        3.4    N                                            200.9          92.0            N                    

  11      F         B        8.9    N                                            175.0          33.2            Y                    

  12      M         W        1.6    N                                            141.0          45.8            Y                    

  13      M         A        4.0    N                                            N/A            19.0            Y                    

  SIT     14        M        B      7.5                                          N              N/A             84.7                 N

  15      F         A        3.7    N                                            203.1          27.1            Y                    

  16      F         B        0.3    N                                            141.5          45.0            Y                    

  17      F         A        16.4   N                                            N/A            65.0            N                    

  LT      18        F        B      −0.3                                         N              191.1           55.4                 N

  19      F         W        3.3    N                                            N/A            77.8            N                    

  20      M         W        −0.8   N                                            N/A            89.2            N                    
  ----------------------------------------------------------------------------------------------------------------------------------------------

Age at ERT corrected by gestational age

HSAT, high sustained antibody titers; LT, low titers; SIT, sustained intermediate titers; ERT, enzyme replacement therapy; LVMI, left ventricular mass index; M, male; F, female; W, White; B, Black; A, Asian; N/A, not available; Y, yes; N, no

[^1]: Co-first authors
